Palliative care 2016

SUMMARY 2

MSCC

RS / SBRT

conv.

RT

Improvement, less selected:

23%

40%

Improvement, myeloma:

71%

76%

Improvement, ambulatory:

63%

62%

Potential Benefit of RS / SBRT for:

► Long-term Survivors (SBRT instead of RS to reduce late toxicity)

► Less Radiosensitive Tumors

► Re-RT, in particular after previous longer-course RT